Código QR (código de barras bidimensional)

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study

Abstract Background Inflammatory breast cancer (IBC) is an aggressive and highly angiogenic disease. Eribulin is a microtubule inhibitor with anti-angiogenic properties. Methods In a phase II trial, we examined the efficacy of an eribulin-containing neoadjuvant regimen (eribulin- > doxorubicin plus...

Fuld beskrivelse

Na minha lista:
Principais autores: Kristina Fanucci, Eren D. Yeh, Ruichao Shi, Lei Qin, Camden P. Bay, Molly DiLullo, Ashka Patel, McKenna Moore, Zachary T. Herbert, Beth T. Harrison, Faina Nakhlis, Jennifer Bellon, Laura Warren, Jennifer L. Guerriero, Sara M. Tolaney, Meredith Regan, Beth Overmoyer, Steven Van Laere, Filipa Lynce
Format: Artigo
Sprog:Inglês
Udgivet: BMC 2025-09-01
Serier:Breast Cancer Research
Fag:
Eribulin
Doxorubicin
Cyclophosphamide
Neoadjuvant therapy
HER2-negative
Inflammatory Breast Cancer
Online adgang:https://doi.org/10.1186/s13058-025-02108-4
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker